Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Jefferam1on Feb 05, 2018 1:53pm
102 Views
Post# 27505222

RE:RE:Time to get some stink bids in

RE:RE:Time to get some stink bids inI agree, it's not likely for ATE to go down to 0.15 but let's take todays activities as an example. One buyer happens to buy 350,000 shares at market price, Price jumps up 0.03 (15%) to 0.22.
Just as easily, one seller could dump 350,000 shares causing a dip by 0.03 to 0.16.

My point was that, like any penny stock there will be volatility especially when we have lower volume.
On the bright side, we are down to 5 more days of administering medication followed by 2 more weeks of observation. Time is counting down. Risk of negative side effects is WAY down.
Now this is the ideal time for people on the fence to get in. At least to put in a small too modest position. If you wait any longer, you run the risk of missing the big gap up. News is coming in 4 weeks or less and this will start to run soon. If I wasn't fully invested, getting in this week at 0.20 or less is a bargain. Even though I say it's possible to dip lower, don't count on it, you might find yourself on the outside looking in wishing you hadn't worried about the 1 or 2 pennies you could have saved.

Exciting times ahead.

Bullboard Posts